Regulus Therapeutics

@RegulusRx

Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.

San Diego, Calif.
Vrijeme pridruživanja: lipanj 2011.

Tweetovi

Blokirali ste korisnika/cu @RegulusRx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @RegulusRx

  1. 17. lip 2016.

    Connecting you with us - is continuing to push the envelope forward. Check out our new website at

    Poništi
  2. 7. lip 2016.

    interim data on RG-101 for the tx of shows significant virologic responses through 24 weeks of follow-up

    Poništi
  3. 7. lip 2016.

    “The data strengthens our conviction in the clinical utility of RG-101 to shorten oral tx regimens to 4 wks or less” CEO Grint

    Poništi
  4. 7. lip 2016.

    announces top-line results from primary endpoint analysis of Ph 2 RG-101 for the tx of . Read more:

    Poništi
  5. 2. svi 2016.

    Tune in at 5pm ET as management talks 2016 Q1 results, RG-101, RG-012 and pipeline. Listen here:

    Poništi
  6. 2. svi 2016.

    Lots to come in 2016 – updates on RG-101 in , RG-012 Ph2 study in , & nomination of potential 4th candidate

    Poništi
  7. 2. svi 2016.

    “2016 is shaping up to be a pivotal year for . RG-101 remains a focus with potential to be a backbone of treatment” CEO Paul Grint

    Poništi
  8. 2. svi 2016.

    reports 2016 Q1 financial results as well updates on RG-101 in , RG-012 in & pipeline

    Poništi
  9. 20. tra 2016.

    Today, CEO Paul Grint will be speaking on emerging anti-viral agents at the FBR Healthcare Series at 11:30am ET in NYC.

    Poništi
  10. 17. tra 2016.

    Thanks for the great time and Barcelona! It was exciting to hear new & discoveries from experts.

    Poništi
  11. 15. tra 2016.
    Poništi
  12. 15. tra 2016.

    The data supports the potential of RG-101 to be a backbone agent in combination w/ all classes of oral therapies. ~ CEO

    Poništi
  13. 15. tra 2016.

    interim Ph2 data @ shows continued high response rates to RG-101 through 24 weeks in patients

    Poništi
  14. 15. tra 2016.

    is highlighted as part of the press program! Check out RG-101 potential Tx for

    Poništi
  15. 14. tra 2016.

    Dr. Femke Stelma, a key investigator in our new RG-101 data, will be speaking at ’s Early Morning Workshop tomorrow at 7:30am CET!

    Poništi
  16. 14. tra 2016.

    We are pleased to be a part of the press program, showcasing our new on RG-101 for the tx of . Stay tuned for more info!

    Poništi
  17. 14. tra 2016.

    is giving an oral presentation on the latest RG-101 data at at 8:45am CET tomorrow. More info here:

    Poništi
  18. 13. tra 2016.

    HCV tx can take months. Further updates on shortened regimen at !

    Poništi
  19. 12. tra 2016.

    is headed to Barcelona! ✈ Thrilled to be a part of the conversation at . Stay tuned for updates & new data on RG-101

    Poništi
  20. 11. tra 2016.

    : is a worldwide issue. 🌎 130-150 million people globally have chronic infection. More here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·